During follow-up, SGTL2 inhibitors and sacubitril/valsartan were initiated in patients who persisted in the category of HfrEF or patients with associated type 2 diabetes mellitus and indication for SGLT2 inhibitors. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.